| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3873015 | The Journal of Urology | 2010 | 9 Pages |
Abstract
Considering that recombinant interleukin-2 based immunocytokines are now being investigated in several clinical trials in patients with cancer alone or combined with chemotherapy our preclinical results provide a motivation to study F8-IL2 combined with sunitinib in clinical trials in patients with kidney cancer.
Keywords
PBSIL2NIBSCEDARCCSIPnatural killersodium dodecyl sulfate-polyacrylamide gel electrophoresisSDS-PAGEHumaninterferonIFNInterleukin-2SunitinibRenal cellCytokinesPhosphate buffered salineNational Institute for Biological Standards and ControlExtracellular matrix proteinsoptical densityRenal cell carcinomaCarcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Katharina Frey, Christoph Schliemann, Kathrin Schwager, Raffaella Giavazzi, Manfred Johannsen, Dario Neri,